Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
50 hedge funds and large institutions have $136M invested in Esperion Therapeutics in 2014 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
16% more funds holding
Funds holding: 43 → 50 (+7)
0% more capital inflows, than outflows
Capital inflows: $6.6M | Capital outflows: $6.58M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
8.67% less ownership
Funds ownership: 35.97% → 27.3% (-8.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EverPoint Asset Management
Stamford,
Connecticut
|
+$1.75M |
| 2 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$1.32M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
+$1.1M |
| 4 |
Jane Street
New York
|
+$650K |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$477K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Polar Capital
London,
United Kingdom
|
-$5.16M |
| 2 |
Wasatch Advisors
Salt Lake City,
Utah
|
-$318K |
| 3 |
SIM
SSI Investment Management
Los Angeles,
California
|
-$283K |
| 4 |
Morgan Stanley
New York
|
-$229K |
| 5 |
PAAMCP
Pacific Alternative Asset Management Company (PAAMCO)
Irvine,
California
|
-$197K |
ESPR Hedge Fund Activity: Q3 2014 in Review
50 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q3 2014, worth a combined $136M — up 54% from $88M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ESPR positions and 4 closed out — a net gain of 7 holders — while 15 added to existing stakes and 15 trimmed.
The largest buyer was EverPoint Asset Management, opening a new position worth an estimated $1.75M. The largest seller was Polar Capital, exiting entirely with an estimated $5.16M sold.
- 50 institutional investors held Esperion Therapeutics (ESPR) as of Q3 2014, up from 43 in Q2 2014.
- Funds reported $136M of Esperion Therapeutics stock for Q3 2014, up 54% quarter-over-quarter.
- 11 funds opened new Esperion Therapeutics positions in Q3 2014 and 4 closed out, a net change of +7 holders.
- The largest Esperion Therapeutics buyer in Q3 2014 was EverPoint Asset Management, an estimated $1.75M added.
- The largest Esperion Therapeutics seller in Q3 2014 was Polar Capital, an estimated $5.16M sold.
Based on aggregated 13F filings for Q3 2014.